Skip to main content
SpringerLink
Log in

Metergoline, naloxone, and sodium valproate did not modify arginine vasopressin response to insulin-induced hypoglycemia in man

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The present study was carried out in order to determine whether insulin-induced hypoglycemia exerts its stimulatory effect on plasma concentrations of arginine vasopressin (AVP) by interacting with a serotonergic, a GABA-ergic or an opioid pathway. For this purpose, the effect of the serotonergic antagonist metergoline (10 mg/day for 4 days po), the GABA-ergic agonist sodium valproate (600 mg in three divided doses po) and the opioid-receptor blocker naloxone (10 mg in a iv bolus) on the AVP response during an insulin (0.15 lU/kg bw) tolerance test (ITT) was evaluated in three groups of 6 normal men each. In all men, control ITTs were performed without drug treatments. Basal and ITT-stimulated AVP secretion was not modified by drug administration, suggesting that serotonergic, GABAergic and naloxone-sensitive opioid receptors are not involved in the regulation of AVP secretion in response to insulin-induced hypoglycemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baylis P.H., Zerbe R.L., Robertson G.L. Arginine vasopressin response to insulin-induced hypoglycemia in man. J. Clin. Endocrinol. Metab. 53: 935, 1981.

    Article  CAS  PubMed  Google Scholar 

  2. Tappaz M., Bronwnstein M.J., Kopin I. Glutamate decarboxylase (GAD) and x-aminobutyric acid (GABA) in discrete nuclei of hypothalamus and substantia nigra. Brain Res. 125: 109, 1977.

    Article  CAS  PubMed  Google Scholar 

  3. Palacios J.M., Wamsley J.K., Kuhar M.J. High affinity GABA receptors-autoradiographic localization. Brain Res. 222: 285, 1981.

    Article  CAS  PubMed  Google Scholar 

  4. Bicknell R.J. Endogenous opioid peptides and hypothalamic neuroendocrine neurones. J. Endocrinol. 107: 437, 1985.

    Article  CAS  PubMed  Google Scholar 

  5. Kamoi K., Robertson G.L. Opiates and vasopressin secretion. In: Schrier R.W. (ed.), Vasopressin. Raven Press, New York, 1985, p. 259.

    Google Scholar 

  6. van den Pol A.N. Dual ultrastructural localization of two neurotransmitterrelated antigens: colloid gold labeled neurophysin immunoreactive supraoptic neurons receive peroxidase labeled glutamate decarboxylase or gold labeled GABA immunoreactive synapses. J. Neurosci. 5: 2940, 1985.

    PubMed  Google Scholar 

  7. van Wimersma Greidanus T.B., ten Haaf J.A., Mens W.B.J. The regulation of the function of the posterior pituitary with special reference to the role of opioid peptides. Front. Horm. Res. 14: 197, 1985.

    Google Scholar 

  8. De Souza E.B. Serotonin and dopamine receptors in the rat pituitary gland; autoradiographic identification, characterization, and localization. Endocrinology 119: 1534, 1986.

    Article  PubMed  Google Scholar 

  9. Theodosis D.T., Paut L., Tappaz M.L. Immunocytochemical analysis of the gabaergic innervation of oxytocin and vasopressin-secreting neurons in the rat supraoptic nucleus. Neuroscience 19: 207, 1986.

    Article  CAS  PubMed  Google Scholar 

  10. Mason W.T., Poulain D., Cobbett P. γ-aminobutyric acid as an inhibitory neurotransmitter in the rat supraoptic necleus: intracellular recordings in the hypothalamic slice. Neurosci. Lett. 73: 259, 1987.

    Article  CAS  PubMed  Google Scholar 

  11. Gibbs D.M., Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res. 280: 176, 1983.

    Article  CAS  PubMed  Google Scholar 

  12. Steardo L., Iovino M., Hunnicutt E. Evidence for a 5-HT involvement in vasopressin release from neurohypophysis of rats. 15th Annual Meeting of the Society of Neuroscience, 1985, p. 44.

  13. Steardo L., Iovino M. Vasopressin release after enhanced serotonergic transmission is not due to activation of the peripheral renin- angiotensin system. Brain Res. 382: 145, 1986.

    Article  CAS  PubMed  Google Scholar 

  14. Sladek C.D., Armstrong W.E. /-aminobutyric acid antagonists stimulate vasopressin release from organ-cultured hypothalamo-neurohypophyseal expiants. Endocrinology 120: 1576, 1987.

    Article  CAS  PubMed  Google Scholar 

  15. Van der Laan J.W., de Boer T., Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J. Neurochem. 32: 1769, 1979.

    Google Scholar 

  16. Beretta C., Ferrini R., Glässer A.H. 1, 6-dimethyl-8-carbobenzyl-oxy-aminomethyl-10-ergo- line, a potent and long-acting 5-hydroxy-tryptamine antagonist. Nature 207: 421, 1965.

    Article  CAS  PubMed  Google Scholar 

  17. Fuxe K., Agnati L., Everitt B. Effects of methergoline on central monoamine neurons. Evidence for a selective blockade of central 5-HT receptors. Neurosci. Lett. 1: 283, 1975.

    CAS  Google Scholar 

  18. Blumberg H., Dayton H.B. Naloxone and related compounds. In: Kosterliz H.W., Collier H.O.J., Villareal J.E. (Eds.), Agonist and antagonist actions of narcotic analgesic drugs. University Park Press, Baltimora, 1973, p. 110.

    Google Scholar 

  19. Chiodera P., Louis F., Legros J.J. Simultaneous radioimmunoassay for plasma argininevasopressin and oxytocin using DEAE sephadex A 25 extraction. J. Endocrinol. Invest. 7: 287, 1984.

    CAS  PubMed  Google Scholar 

  20. Cavagnini F., Raggi U., Micossi P., Di Landro A., Invitti C. Effect of antiserotoninergic drug, metergoline, on the ACTH and Cortisol response to insulin hypoglycemia and lysine-vasopressin in man. J. Clin. Endocrinol. Metab. 43: 306, 1976.

    Article  CAS  PubMed  Google Scholar 

  21. Serri O., Rasio E., Somma M. Effects of naloxone on insulin-induced release of pituitary hormones. J. Clin. Endocrinol. Metab. 53: 206, 1981.

    Article  CAS  PubMed  Google Scholar 

  22. Petraglia F., Bakalakis S., Facchinetti F., Volpe A., Muller E.E., Genazzani A.R. Effects of sodium valproate and diazepam on beta-en- dorphin, beta-lipotropin and Cortisol secretion induced by hypoglycemic stress in humans. Neuroendocrinology 44: 320, 1986.

    Article  CAS  PubMed  Google Scholar 

  23. Kao C.P., N-Siang Jiang, Carpenter P.C. Human corticotropin (ACTH) radioimmunoassay with synthetic 1–24 ACTH. Clin. Chem. 25: 1267, 1979.

    CAS  PubMed  Google Scholar 

  24. Schalch D.S., Parker M.L. A sensitive double antibody immunoassay for human growth hormone in plasma. Nature 203: 1141, 1964.

    Article  CAS  PubMed  Google Scholar 

  25. Baylis P.H. Posterior pituitary function in health and disease. In: Scanion M.F. (ed.), Neuroendocrinology. Saunders, Philadelphia, 1983, p. 747.

    Google Scholar 

  26. Coiro V., Butturini U., Gnudi A., Delsignore R., Volpi R., Chiodera P. Nicotinic-cholinergic involvement in arginine-vasopressin response to insulin-induced hypoglycemia in normal men. Metabolism 35: 577, 1986.

    Article  CAS  PubMed  Google Scholar 

  27. Adler G.K., Majzoub J.A. Influence of infused hypertonic saline on the response to insulin-induced hypoglycemia in man. J. Clin. Endocrinol. Metab. 65: 116, 1987.

    Article  CAS  PubMed  Google Scholar 

  28. Chiodera P., Coiro V. Lack of effect of bromocriptine and domperidone on arginine-vasopressin response to insulin-induced hypoglycemia in normal men. Psychoneuroendocrinology 12: 225, 1987.

    Article  CAS  PubMed  Google Scholar 

  29. Brennan T.J., Haywood J.R. GABAergic inhibition of hypertonic saline-induced vasopressin-dependent hypertension. J. Pharmacol. Exper. Therap. 233: 663, 1985.

    CAS  Google Scholar 

  30. lovino M., Steardo L. Effect of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat. Eur. J. Pharmacol. 113: 99, 1985.

    Article  Google Scholar 

  31. Lightman S.L., Langdon N., Forsling M.L. Effects of the opiate antagonist naloxone and the enkephalin analog DAMME on the vasopressin response to a hypertonic stimulus in man. J. Clin. Endocrinol. Metab. 51: 1447, 1980.

    Article  CAS  PubMed  Google Scholar 

  32. Lightman S.L., Forsling M.L. Evidence for endogenous opioid control of vasopressin release in man. J. Clin. Endocrinol. Metab. 50: 251, 1980.

    Article  Google Scholar 

  33. Unger T., Bles F., Ganten D., Lang R.E., Retting R., Schwab N.A. GABAergic stimulation inhibits central actions of angiotensin II: pressor responses, drinking and release of vasopressin. Eur. J. Pharmacol. 90: 1, 1983.

    Article  CAS  PubMed  Google Scholar 

  34. Goodman Gilman A., Goodman L.S., Gilman A. The pharmacological basis of therapeutics. Mac Millan, New York, 1980, p. 946.

    Google Scholar 

  35. Goodman Gilman A., Goodman L.S., Gilman A. The pharmacological basis of therapeutics. Mac Millan, New York, 1980, p. 462.

    Google Scholar 

  36. Tepperman F.S., Hirst M., Smith P. Brain and serum levels of naloxone following peripheral administration. Life Sci. 33: 1091, 1983.

    Article  CAS  PubMed  Google Scholar 

  37. van Houten M., Posner B.I., Kopriwa B.M., Brawer J.R. Insulin-binding sites in the rat brain: in vivo localization to the circumventricular organs by quantitative radiography. Endocrinology 105: 666, 1979.

    Article  PubMed  Google Scholar 

  38. van Houten M., Posner B.J., Kopriwa B.M., Brawer J.R. Insulin binding sites localized nerve terminals in rat median eminence and arcuate nucleus. Science 207: 1081, 1980.

    Article  PubMed  Google Scholar 

  39. van Houten M., Nance D.M., Gauthier S., Posner B.I. Origin of insulin-receptive nerve terminals in rat median eminence. Endocrinology 113: 1393, 1983.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cattedra di Endocrinologia e Patologia Costituzionale, Ospedale di Parma, Università di Parma, Via Gramsci 14, 43100, Parma, Italy

    Paolo Chiodera, A. Gnudi, L. d’Amato, L. Bianconi & R. Minelli

  2. Cattedra di Clinica Medica Generale, Ospedale di Parma, 43100, Parma

    R. Volpi, G. Pioli, G. Gelmini & V. Coiro

  3. Cattedra di Psichiatria, Università di Parma, Ospedale di Parma, 43100, Parma

    C. Marchesi

  4. Divisione di Medicina Interna, Ospedale di Parma, 43100, Parma

    P. Muzzetto

  5. Divisione di Medicina Interna, Ospedale di Piacenza, 29100, Piacenza, Italy

    A. Castelli

Authors
  1. Paolo Chiodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Gnudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Volpi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. d’Amato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Marchesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Pioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Muzzetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Castelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Bianconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Minelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Gelmini
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. V. Coiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiodera, P., Gnudi, A., Volpi, R. et al. Metergoline, naloxone, and sodium valproate did not modify arginine vasopressin response to insulin-induced hypoglycemia in man. J Endocrinol Invest 11, 365–369 (1988). https://doi.org/10.1007/BF03349056

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03349056

En]Keywords

Search

Navigation